Who
James Cassella V
Chief Development Officer
Company insider
Files Form 4 as: Chief Development Officer, Trevi Therapeutics; Chief Development Officer, Concert Pharmaceuticals; EVP, R&D and CSO, Alexza Pharmaceuticals.
In numbers
- Trades disclosed
- 97
- Buys
- 0
- Sells
- 18
- Bought
- $0
- Sold
- $659K
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 13 Mar 2006
- Last trade
- 19 Feb 2026
- Last filed
- 20 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 Feb 2026filed 20 Feb 2026 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —215,000 at $0.00 | filing |
| 19 Feb 2026filed 20 Feb 2026 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —215,000 at $0.00 | filing |
| 18 Feb 2025filed 20 Feb 2025 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —257,500 at $0.00 | filing |
| 30 Sep 2024filed 1 Oct 2024 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —400,000 at $0.00 | filing |
| 13 Jun 2024filed 14 Jun 2024 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 28 Jun 2023filed 30 Jun 2023 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 6 Mar 2023filed 6 Mar 2023 | Concert Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —34,700 | filing |
| 6 Mar 2023filed 6 Mar 2023 | Concert Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —140,000 | filing |
| 6 Mar 2023filed 6 Mar 2023 | Concert Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —50,000 | filing |
| 6 Mar 2023filed 6 Mar 2023 | Concert Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —70,000 | filing |
| 6 Mar 2023filed 6 Mar 2023 | Concert Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —49,500 | filing |
| 6 Mar 2023filed 6 Mar 2023 | Concert Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —75,000 | filing |
| 6 Mar 2023filed 6 Mar 2023 | Concert Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —42,430 | filing |
| 6 Mar 2023filed 6 Mar 2023 | Concert Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —60,400 | filing |
| 6 Mar 2023filed 6 Mar 2023 | Concert Pharmaceuticals | SEC FORM 4 Code U | —80,595 | filing |
| 6 Mar 2023filed 6 Mar 2023 | Concert Pharmaceuticals | SEC FORM 4 Code D | —57,766 | filing |
| 15 Feb 2023filed 16 Feb 2023 | Concert Pharmaceuticals | SEC FORM 4 Sold | $31K3,762 at $8.34 | filing |
| 30 Jan 2023filed 31 Jan 2023 | Concert Pharmaceuticals | SEC FORM 4 Sold | $84K10,106 at $8.35 | filing |
| 6 Jan 2023filed 9 Jan 2023 | Concert Pharmaceuticals | SEC FORM 4 Sold | $21K2,893 at $7.25 | filing |
| 23 Jun 2022filed 1 Jul 2022 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.